Adjuncts for Ovarian Stimulation

doi:10.1017/9781316477021.023

Chapter 20 - Adjuncts for Ovarian Stimulation

from Section 4 - Non-conventional Forms Used during Ovarian Stimulation

Published online by Cambridge University Press: 14 April 2022

Alexander M. Quaas and

David R. Meldrum

Edited by

Mohamed Aboulghar and

Botros Rizk

Show author details

Mohamed Aboulghar: Affiliation:
University of Cairo IVF Centre
Botros Rizk: Affiliation:
University of South Alabama

Book contents

Get access

Summary

Clomiphene (clomifene) citrate (CC) and follicle-stimulating hormone (FSH) have traditionally been considered the two main modalities used for ovarian stimulation (OS). However, many adjuncts have been used to maximize the convenience and effectiveness of these two agents, often specifically targeted to subsets of women undergoing stimulation. Most of these adjuncts are not officially approved for these indications. Therefore, educators and practitioners must take it upon themselves to assess the evidence supporting their use, and make treatment recommendations and decisions accordingly. We have outlined in an editorial in Fertility and Sterility a process to aid in this endeavor [1]. Decisions are based not only on randomized clinical trials (RCT), but also on other basic science and clinical evidence supporting their use.

Information

Type: Chapter
Information: Ovarian Stimulation , pp. 189 - 198

DOI: https://doi.org/10.1017/9781316477021.023 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Meldrum, DR, Chang, RJ, de Ziegler, D, et al. Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs? Fertil Steril 2009;92:13–18.Google Scholar

Meldrum, DR, Wisot, A, Hamilton, F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989;51:455–459.Google Scholar

Hughes, EG, Fedorkow, DM, Daya, S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896.Google Scholar

Tarlatzis, BC, Fauser, BC, Kolibianakis, EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333–340.Google Scholar

Lambalk, CB, Banga, FR, Huirne, JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update 2017;23:560–579.Google Scholar

Biljan, MM, Mahutte, NG, Dean, N, et al. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril 1998;70:1063–1069.CrossRef Google Scholar PubMed

van Heusden, AM, Fauser, BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999;59:237–243.Google Scholar

de Ziegler, D, Jaaskelainen, AS, Brioschi, PA, Fanchin, R, Bulletti, C. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod 1998;13:561–564.Google Scholar

Fanchin, R, Salomon, L, Castelo-Branco, A, et al. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;18:2698–2703.Google Scholar

Frattarelli, JL, Hill, MJ, McWilliams, GD, et al. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril 2008;89:1118–1122.Google Scholar

Daly, DC, Walters, CA, Soto-Albors, CE, Tohan, N, Riddick, DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984;41:844–848.Google Scholar

Parsanezhad, ME, Alborzi, S, Motazedian, S, Omrani, G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril 2002;78:1001–1004.Google Scholar

Elnashar, A, Abdelmageed, E, Fayed, M, Sharaf, M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 2006;21:1805–1808.Google Scholar

Keay, SD, Lenton, EA, Cooke, ID, Hull, MG, Jenkins, JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod 2001;16:1861–1865.Google Scholar

Thurston, LM, Norgate, DP, Jonas, KC, et al. Ovarian modulators of type 1 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity and intra-follicular cortisol:cortisone ratios correlate with the clinical outcome of IVF. Hum Reprod 2003;18:1603–1612.Google Scholar

Lewicka, S, von Hagens, C, Hettinger, U, et al. Cortisol and cortisone in human follicular fluid and serum and the outcome of IVF treatment. Hum Reprod 2003;18:1613–1617.Google Scholar

Simerman, AA, Hill, DL, Grogan, TR, et al. Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2015;103:249–257.Google Scholar

Palomba, S, Falbo, A, La Sala, GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267–276.Google Scholar

Agrawal, R, Jacobs, H, Payne, N, Conway, G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 2002;78:1164–1169.Google Scholar

Creanga, AA, Bradley, HM, McCormick, C, Witkop, CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111:959–968.Google Scholar

Stadtmauer, LA, Toma, SK, Riehl, RM, Talbert, LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505–509.Google Scholar

Tang, T, Glanville, J, Orsi, N, Barth, JH, Balen, AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006;21:1416–1425.Google Scholar

Jakubowicz, DJ, Seppala, M, Jakubowicz, S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1126–1133.Google Scholar

Cermik, D, Selam, B, Taylor, HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:238–243.Google Scholar

Jakubowicz, DJ, Iuorno, MJ, Jakubowicz, S, Roberts, KA, Nestler, JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–529.Google Scholar

De Leo, V, la Marca, A, Ditto, A, Morgante, G, Cianci, A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:282–285.Google Scholar

Meldrum, DR, Scott, RT, Jr., Levy, MJ, Alper, MM, Noyes, N. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss. Fertil Steril 2009;91:1963–1965.Google Scholar

Acevedo, B, Sanchez, M, Gomez, JL, et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004;82:343–347.Google Scholar

The ganirelix dose-finding group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998;13:3023–3031.Google Scholar

Kolibianakis, EM, Zikopoulos, K, Schiettecatte, J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004;19:24902496.Google Scholar

Coomarasamy, A, Afnan, M, Cheema, D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008;23:310–315.Google Scholar

Thompson, KA, LaPolt, PS, River, J, et al. Gonadotropin requirements of the developing follicle. Fertil Steril 1995;63:273–276.Google Scholar

Rubinstein, M, Marazzi, A, Polak de Fried, E. Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay. Fertil Steril 1999;71:825–829.Google Scholar

Ebbesen, SM, Zachariae, R, Mehlsen, MY, et al. Stressful life events are associated with a poor in-vitro fertilization (IVF) outcome: a prospective study. Hum Reprod 2009;24:2173–2182.Google Scholar

Siristatidis, CS, Basios, G, Pergialiotis, V, Vogiatzi, P. Aspirin for in vitro fertilisation. Cochrane Database Syst Rev 2016;11:CD004832.Google Scholar

Varnagy, A, Bodis, J, Manfai, Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010;93:2281–2284.Google Scholar

Bencomo, E, Perez, R, Arteaga, MF, et al. Apoptosis of cultured granulosa-lutein cells is reduced by insulin-like growth factor I and may correlate with embryo fragmentation and pregnancy rate. Fertil Steril 2006;85:474–480.Google Scholar

Harper, K, Proctor, M, Hughes, E. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev 2003;3:CD000099.Google Scholar

Tesarik, J, Hazout, A, Mendoza, C. Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Hum Reprod 2005;20:2536–2541.Google Scholar

Kolibianakis, EM, Venetis, CA, Diedrich, K, Tarlatzis, BC, Griesinger, G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009;15:613–622.Google Scholar

Li, XL, Wang, L, Lv, F, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6443.Google Scholar

Meldrum, DR, Quaas, AM, Su, HI. Why is growth hormone underutilized for our most difficult IVF couples? Fertil Steril 2018;110:1261–1262.Google Scholar

Alvarez, C, Marti-Bonmati, L, Novella-Maestre, E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–2937.Google Scholar

Levin, ER, Rosen, GF, Cassidenti, DL, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978–1985.Google Scholar

Ferraretti, AP, Gianaroli, L, Diotallevi, L, Festi, C, Trounson, A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180–183.Google Scholar

Alvarez, C, Alonso-Muriel, I, Garcia, G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210–3214.Google Scholar

Vendola, KA, Zhou, J, Adesanya, OO, Weil, SJ, Bondy, CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622–2629.Google Scholar

Balasch, J, Fabregues, F, Penarrubia, J, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006;21:1884–1893.Google Scholar

Kim, CH, Howles, CM, Lee, HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril 2011;95:679–683.Google Scholar

Garcia-Velasco, JA, Moreno, L, Pacheco, A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82–87.Google Scholar

Schoolcraft, WB, Surrey, ES, Minjarez, DA, Stevens, JM, Gardner, DK. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? Fertil Steril 2008;89:151–156.Google Scholar

Song, Y, Li, Z, Wu, X, et al. Effectiveness of the antagonist/letrozole protocol for treating poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Gynecol Endocrinol 2014;30:330–334.Google Scholar

Frattarelli, JL, Gerber, MD. Basal and cycle androgen levels correlate with in vitro fertilization stimulation parameters but do not predict pregnancy outcome. Fertil Steril 2006;86:51–57.Google Scholar

Barad, D, Gleicher, N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006;21:2845–2849.Google Scholar

Barad, D, Brill, H, Gleicher, N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007;24:629–634.Google Scholar

Nagels, HE, Rishworth, JR, Siristatidis, CS, Kroon, B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015;11:CD009749.Google Scholar

Paulson, RJ. At last, an orally active gonadotropin-releasing hormone antagonist. Fertil Steril 2019;111:30–31.Google Scholar

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.